{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 1,
        "evidence": "Patients who received routine anticancer therapy (i.e., radiotherapy or chemotherapy) also were eligible."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were included and received a single dose of SGM-101 at least 24 h before surgery."
      },
      "Objective": {
        "score": 1,
        "evidence": "A phase I/II study was designed to determine the optimal imaging dose of SGM-101 for intraoperative fluorescence imaging of primary and recurrent CRC."
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Thirty-seven patients with CRC were included in the analysis."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Thirty-seven patients with CRC were included in the analysis."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The highest mean intraoperative tumor-to-background ratio (TBR) of 1.9 ( p =\u20090.019) was seen in the 10-mg dose."
      },
      "Harms": {
        "score": 1,
        "evidence": "Safety assessments were performed and SGM-101 efficacy was evaluated per dose level to determine the most optimal imaging dose."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 9,
    "max_score": 25
  },
  "model": "gpt-4o"
}